Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Evolus, Inc. (NASDAQ:EOLS) has received an average consensus recommendation of "Hold" from five analysts, with one sell rating, one hold rating, and three buy ratings.
• The average 1-year target price for Evolus stock is $21.25, with varying price targets set by different analysts, including a recent reduction to $20.00 by HC Wainwright.
• Insider activity has been notable, with CMO Tomoko Yamagishi-Dressler selling shares and Director Brady Stewart increasing their holdings by 51.17% in recent transactions.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $21.25.

EOLS has been the subject of several analyst reports. HC Wainwright reduced their target price on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. BTIG Research reiterated a "buy" rating and set a $18.00 price objective on shares of Evolus in a research note on Monday, September 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Evolus in a research report on Saturday, September 27th. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC reiterated a "hold" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, August 6th.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the transaction, the chief marketing officer directly owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady Stewart purchased 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The stock was bought at an average price of $6.82 per share, with a total value of $204,600.00. Following the acquisition, the director directly owned 88,629 shares of the company's stock, valued at approximately $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Evolus

Large investors have recently bought and sold shares of the company. PDT Partners LLC acquired a new position in shares of Evolus during the 1st quarter worth about $730,000. GAMMA Investing LLC lifted its stake in Evolus by 1,765.9% in the first quarter. GAMMA Investing LLC now owns 18,622 shares of the company's stock valued at $224,000 after acquiring an additional 17,624 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Evolus by 5.4% in the first quarter. Russell Investments Group Ltd. now owns 118,085 shares of the company's stock valued at $1,421,000 after buying an additional 6,015 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Evolus in the first quarter valued at approximately $5,851,000. Finally, Rhumbline Advisers lifted its holdings in Evolus by 4.1% during the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock valued at $1,004,000 after purchasing an additional 3,287 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Trading Up 4.2%

NASDAQ EOLS traded up $0.26 during trading on Friday, reaching $6.50. The company's stock had a trading volume of 792,877 shares, compared to its average volume of 1,031,706. Evolus has a 1-year low of $5.71 and a 1-year high of $17.82. The business has a 50-day moving average price of $7.13 and a 200-day moving average price of $9.19. The stock has a market capitalization of $420.45 million, a PE ratio of -6.63 and a beta of 1.04.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.